Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells

Biochemical and Biophysical Research Communications

Volumn 405, Issue 3, 2011, Pages 377-381

  Hisatsune, Akinori ^a   Nakayama, Hideki ^a   Kawasaki, Mitsuru ^a   Horie, Ichiro ^a   Miyata, Takeshi ^b   Isohama, Yoichiro ^a   Kim, Kwang Chul ^c   Katsuki, Hiroshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SOJO UNIVERSITY   (Japan)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cell signaling; EGF; EGF receptor; MUC1; Receptor internalization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MUC1 ANTIBODY; MUCIN 1; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTERNALIZATION; PANCREAS CANCER; PINOCYTOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MUCIN-1; NEOPLASMS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79951578877     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.01.029     Document Type: Article

References (45)

1. Baldus S.E., Engelmann K., Hanisch F.G. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit. Rev. Clin. Lab. Sci. 2004, 41:189-231.
2. Ligtenberg M.J., Kruijshaar L., Buijs F., van Meijer M., Litvinov S.V., Hilkens J. Cell-associated episialin is a complex containing two proteins derived from a common precursor. J. Biol. Chem. 1992, 267:6171-6177.
3. Macao B., Johansson D.G., Hansson G.C., Hard T. Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin. Nat. Struct. Mol. Biol. 2006, 13:71-76.
4. Mikami Y., Hisatsune A., Tashiro T., Isohama Y., Katsuki H. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem. Biophys. Res. Commun. 2009, 379:1060-1065.
5. Schroeder J.A., Masri A.A., Adriance M.C., Tessier J.C., Kotlarczyk K.L., Thompson M.C., Gendler S.J. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004, 23:5739-5747.
6. Satoh S., Hinoda Y., Hayashi T., Burdick M.D., Imai K., Hollingsworth M.A. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int. J. Cancer 2000, 88:507-518.
7. Kohlgraf K.G., Gawron A.J., Higashi M., Meza J.L., Burdick M.D., Kitajima S., Kelly D.L., Caffrey T.C., Hollingsworth M.A. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res. 2003, 63:5011-5020.
8. Tsutsumida H., Swanson B.J., Singh P.K., Caffrey T.C., Kitajima S., Goto M., Yonezawa S., Hollingsworth M.A. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Clin. Cancer Res. 2006, 12:2976-2987.
9. Schroeder J.A., Thompson M.C., Gardner M.M., Gendler S.J. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J. Biol. Chem. 2001, 276:13057-13064.
10. Wei X., Xu H., Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol. Cell 2006, 21:295-305.
11. Ren J., Agata N., Chen D., Li Y., Yu W.H., Huang L., Raina D., Chen W., Kharbanda S., Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004, 5:163-175.
12. Wei X., Xu H., Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005, 7:167-178.
13. Pochampalli M.R., Bitler B.G., Schroeder J.A. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res. 2007, 67:6591-6598.
14. Pochampalli M.R., el Bejjani R.M., Schroeder J.A. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007, 26:1693-1701.
15. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., Eckhardt S.G., Tolcher A., Britten C.D., Denis L., Ferrante K., Von Hoff D.D., Silberman S., Rowinsky E.K. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001, 19:3267-3279.
16. Tobita K., Kijima H., Dowaki S., Kashiwagi H., Ohtani Y., Oida Y., Yamazaki H., Nakamura M., Ueyama Y., Tanaka M., Inokuchi S., Makuuchi H. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int. J. Mol. Med. 2003, 11:305-309.
17. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., Abbruzzese J., Traxler P., Buchdunger E., Radinsky R., Fidler I.J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000, 60:2926-2935.
18. Solorzano C.C., Baker C.H., Tsan R., Traxler P., Cohen P., Buchdunger E., Killion J.J., Fidler I.J. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 2001, 7:2563-2572.
19. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
20. Hisatsune A., Kawasaki M., Nakayama H., Mikami Y., Miyata T., Isohama Y., Katsuki H., Kim K.C. Internalization of MUC1 by anti-MUC1 antibody from cell membrane through the macropinocytotic pathway. Biochem. Biophys. Res. Commun. 2009, 388:677-682.
21. Matsuzawa Y., Kiuchi Y., Toyomura K., Matsumoto I., Nakamura H., Fujino H., Murayama T., Kawashima T. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf. J. Pharmacol. Sci. 2009, 111:182-192.
22. Sorkin A., von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 2009, 10:609-622.
23. Sigismund S., Woelk T., Puri C., Maspero E., Tacchetti C., Transidico P., Di Fiore P.P., Polo S. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 2005, 102:2760-2765.
24. Sigismund S., Argenzio E., Tosoni D., Cavallaro E., Polo S., Di Fiore P.P. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev. Cell 2008, 15:209-219.
25. Kirkham M., Parton R.G. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim. Biophys. Acta 2005, 1745:273-286.
26. Bryant D.M., Kerr M.C., Hammond L.A., Joseph S.R., Mostov K.E., Teasdale R.D., Stow J.L. EGF induces macropinocytosis and SNX1-modulated recycling of E-cadherin. J. Cell Sci. 2007, 120:1818-1828.
27. Mineo C., Gill G.N., Anderson R.G. Regulated migration of epidermal growth factor receptor from caveolae. J. Biol. Chem. 1999, 274:30636-30643.
28. Staubach S., Razawi H., Hanisch F.G. Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7. Proteomics 2009, 9:2820-2835.
29. Lillehoj E.P., Kim B.T., Kim K.C. Identification of Pseudomonas aeruginosa flagellin as an adhesin for Muc1 mucin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 282:L751-L756.
30. Lillehoj E.P., Kim H., Chun E.Y., Kim K.C. Pseudomonas aeruginosa stimulates phosphorylation of the airway epithelial membrane glycoprotein Muc1 and activates MAP kinase. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L809-L815.
31. Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70:431-457.
32. Lu W., Hisatsune A., Koga T., Kato K., Kuwahara I., Lillehoj E.P., Chen W., Cross A.S., Gendler S.J., Gewirtz A.T., Kim K.C. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J. Immunol. 2006, 176:3890-3894.
33. Ueno K., Koga T., Kato K., Golenbock D.T., Gendler S.J., Kai H., Kim K.C. MUC1 mucin is a negative regulator of toll-like receptor signaling. Am. J. Respir. Cell Mol. Biol. 2008, 38:263-268.
34. Kufe D. Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010, 29:5663-5666.
35. Kamat V., Donaldson J.M., Kari C., Quadros M.R., Lelkes P.I., Chaiken I., Cocklin S., Williams J.C., Papazoglou E., Rodeck U. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol. Ther. 2008, 7:726-733.
36. Liao H.J., Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res. 2009, 69:6179-6183.
37. Yoshida T., Okamoto I., Okabe T., Iwasa T., Satoh T., Nishio K., Fukuoka M., Nakagawa K. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int. J. Cancer 2008, 122:1530-1538.
38. Huet G., Hennebicq-Reig S., de Bolos C., Ulloa F., Lesuffleur T., Barbat A., Carriere V., Kim I., Real F.X., Delannoy P., Zweibaum A. GalNAc-alpha-O-benzyl inhibits NeuAcalpha2-3 glycosylation and blocks the intracellular transport of apical glycoproteins and mucus in differentiated HT-29 cells. J. Cell Biol. 1998, 141:1311-1322.
39. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., Tamai S., Matsubara O., Hatsuse K., Mochizuki H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29:e1-e8.
40. Overholser J.P., Prewett M.C., Hooper A.T., Waksal H.W., Hicklin D.J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89:74-82.
41. Liu L., Cao Y., Tan A., Liao C., Gao F. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials. Cancer Chemother. Pharmacol. 2010, 65:849-861.
42. Hamanaka Y., Suehiro Y., Fukui M., Shikichi K., Imai K., Hinoda Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 2003, 103:97-100.
43. Oei A.L., Moreno M., Verheijen R.H., Sweep F.C., Thomas C.M., Massuger L.F., Mensdorff-Pouilly S. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer 2008, 123:1848-1853.
44. Hirasawa Y., Kohno N., Yokoyama A., Kondo K., Hiwada K., Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 2000, 161:589-594.
45. Mensdorff-Pouilly S., Verstraeten A.A., Kenemans P., Snijdewint F.G., Kok A., Van Kamp G.J., Paul M.A., Van Diest P.J., Meijer S., Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 2000, 18:574-583.